UBS Group Cuts Owens & Minor (NYSE:OMI) Price Target to $13.00

Owens & Minor (NYSE:OMI) had its price target lowered by UBS Group from $25.00 to $13.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on OMI. Barclays reduced their price objective on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 5th. Robert W. Baird reduced their price target on shares of Owens & Minor from $15.00 to $14.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Finally, Citigroup reduced their price target on shares of Owens & Minor from $21.00 to $18.50 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $16.79.

Owens & Minor Stock Performance

Shares of OMI stock opened at $7.45 on Thursday. The company has a debt-to-equity ratio of 2.11, a quick ratio of 0.45 and a current ratio of 1.09. Owens & Minor has a one year low of $7.41 and a one year high of $28.35. The company’s 50-day simple moving average is $12.80 and its 200-day simple moving average is $13.84. The stock has a market capitalization of $574.08 million, a price-to-earnings ratio of -11.45, a PEG ratio of 0.25 and a beta of 0.48.

Insider Transactions at Owens & Minor

In other Owens & Minor news, CFO Jonathan A. Leon sold 5,282 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $11.82, for a total transaction of $62,433.24. Following the sale, the chief financial officer now owns 130,822 shares in the company, valued at approximately $1,546,316.04. The trade was a 3.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.59% of the company’s stock.

Institutional Investors Weigh In On Owens & Minor

A number of institutional investors have recently bought and sold shares of OMI. Freestone Grove Partners LP purchased a new stake in Owens & Minor in the 4th quarter worth approximately $5,125,000. Foundry Partners LLC acquired a new stake in Owens & Minor during the third quarter valued at $5,238,000. Charles Schwab Investment Management Inc. grew its stake in Owens & Minor by 13.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,305,043 shares of the company’s stock valued at $30,127,000 after purchasing an additional 276,807 shares in the last quarter. Norges Bank acquired a new position in Owens & Minor in the 4th quarter worth about $2,465,000. Finally, Algert Global LLC increased its position in Owens & Minor by 189.4% in the 3rd quarter. Algert Global LLC now owns 276,438 shares of the company’s stock worth $4,337,000 after purchasing an additional 180,922 shares during the last quarter. 98.04% of the stock is currently owned by institutional investors and hedge funds.

Owens & Minor Company Profile

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.